日本癌癥治療行業(yè)市場(chǎng)前景及投資研究報(bào)告-培訓(xùn)課件外文版2024.4

INDUSTRIES

&

MARKETSCancerinJapanCHAPTER

01DeathsfromcancerNumberoffatalitiesinJapanin2021,bycauseofdeathNumberoffatalitiesJapan2021,bycauseofdeathNumberoffatalities050,000100,000150,000200,000250,000300,000350,000400,000450,000MalignantneoplasmsHeartdiseases*381,505214,710Senility152,027CerebrovasculardiseasesHeartfailureTrachea/bronchus/lungcancerPneumonia104,59589,95076,21273,19458,489CerebralinfarctionStomachcancerPancreascancerAccidentsColoncancerCardiacarrhythmiasandconductiondisorders41,62438,57938,35536,77332,8044Description:In2021,thenumberoffatalitiesinJapancausedbymalignantneoplasmsamountedtoapproximately381.5thousand.Thatyear,thetotalnumberofdeathsinJapanreachedmorethan1.4millioncases.

ReadmoreNote(s):Japan;2021;*Excludinghypertensiveheartdiseases.ReadmoreSource(s):MHLW(Japan);StatisticsBureauofJapanCrudemortalityrateforcancerinJapanfrom1995to2022(per100,000people)Cancer'scrudedeathrateinJapan1995-2022340320300316.1310.7306.6304.2300.7299.5298.4295.5293.5279.7280258.3260240220200235.22000211.61995200520102014201520162017201820192020202120225Description:In2022,thecrudemortalityrateforcancerinJapanaccountedforarecord-highof316.1per100,000people.Theratehasbeenshowingapersistentupwardtrajectorysince1995.

ReadmoreNote(s):Japan;1995to2022Source(s):JapanCancerSociety;MHLW(Japan)NumberofdeathscausedbymalignantneoplasmsinJapanfrom2012to2021(in1,000s)NumberofmalignantneoplasmscauseddeathsJapan2012-2021450400381.51376.43378.39373.09373.37373.58368.1370.36364.87360.9635030025020015010050020122013201420152016201720182019202020216/statistics/1074677/japan-number-malignant-neoplasms-deathsIn2021,approximately381.5thousanddeathscausedbymalignantneoplasmswererecordedinJapan.ThemostfrequentcauseofcanceroustumorsrelateddeathswaslungcancerforbothmenandwomeninJapanduringthemeasuredperiod.

ReadmoreNote(s):Japan;2012to2021Source(s):CenterforCancerControlandInformationServices;FoundationforPromotionofCancerResearch;MHLW(Japan)NumberofdeathsfromcanceramongmeninJapanin2021,bycancersiteNumberofdeathsfromcanceramongmenJapan2021,bysiteNumberofpersons20,000

30,000010,00040,00050,00060,000LungStomach53,27827,196Pancreas19,33418,18315,91313,217ColonLiverProstateRectum9,8979,6158,8647,6275,549GallbladderandbileductsEsophagusMalignantlymphomaLeukemiaThyroid656Others33,1387Description:In2021,around53.3thousandmeninJapandiedoflungcancer,followedbystomachcancerwithapproximately27.2thousanddeaths.Thyroidcancerwastherarestcauseofmaledeathsin2021with656cases.Thatyear,morethan222thousandmendiedofcancerinJapan.ReadmoreNote(s):Japan;2021Source(s):CenterforCancerControlandInformationServicesNumberofdeathsfromcanceramongwomeninJapanin2021,bycancersiteNumberofdeathsfromcanceramongwomenJapan2021,bysiteNumberofpersons10,00005,00015,00020,00025,000LungPancreas22,93419,245Colon18,590BreastStomach14,80314,428GallbladderandbileductsLiver8,5578,189UterusMalignantlymphomaRectum6,8186,1545,7485,081OvaryLeukemia3,575EsophagusThyroid2,0941,278Others21,5448Description:In2021,morethan22.9thousandwomeninJapandiedoflungcancer,makingupthelargestshareofcancerdeaths.Thyroidcancerwastherarestcauseoffemaledeathsin2021withlessthan1.3thousandcases.Thatyear,thetotalnumberoffemalecancerdeathsamountedtoapproximately159thousandcases.ReadmoreNote(s):Japan;2021Source(s):CenterforCancerControlandInformationServicesCHAPTER

02DiagnosedcancercasesEstimatednumberofcancercasesdiagnosedinJapanin2022,bygender(in1,000s)ProjectednumberofcancercasesJapan2022,bygender700600584500434.94003002001000WomenMen10Description:In2022,theestimatednumberofcancercasesdiagnosedinmenamountedtoaround584thousand.Theprojectednumberofcancercasesofwomenwasmuchlowerinthatyear.

ReadmoreNote(s):Japan;2022Source(s):CancerInformationService;FoundationforPromotionofCancerResearchEstimatednumberofcancercasesdiagnosedinmeninJapanfrom2019to2022(in1,000s)ProjectednumberofcancercasesinmenJapan2019-2022700582.2584577.96005004003002001000572.6201920202021202211Description:In2022,theestimatednumberofcancercasesdiagnosedinmenamountedtoaround584thousand.Thefigureincreasedcomparedtoover572thousandcasesin2019.

ReadmoreNote(s):Japan;2019to2022Source(s):CancerInformationService;FoundationforPromotionofCancerResearchEstimatednumberofcancercasesdiagnosedinwomeninJapanfrom2019to2022(in1,000s)ProjectednumberofcancercasesinwomenJapan2019-2022500444.6434.945040035030025020015010050429.9431.90201920202021202212Description:In2022,theestimatednumberofcancercasesdiagnosedinwomenamountedtoaround434.9thousand.Thefiguredecreasedcomparedtoover444thousandcasesin2019.

ReadmoreNote(s):Japan;2019to2022Source(s):CancerInformationService;FoundationforPromotionofCancerResearchEstimatednumberofcancercasesdiagnosedinmeninJapanin2022,bycancersite(in1,000s)ProjectednumberofmalecancercasesJapan2022,bycancersiteNumberofincidencesinthousands0102030405060708090100110Prostate96.4StomachColon/rectum91.189.5Lung86.3Liver27.5PancreasEsophagus22.622.1KidneyandotherurinaryorgansMalignantlymphomaBladder20.919.918.716.113.412.8OralcavityandpharynxSkinGallbladderandbileducts13Description:In2022,thenumberofprostatecancercasesamongJapanesemenwasestimatedtobehighest,atmorethan96thousand.Followingwerestomachcancer,estimatedtoreachmorethan91thousandcases,andcolonandrectumcancerwithcloseto90thousandcasesthatyear.ReadmoreNote(s):Japan;2022Source(s):CenterforCancerControlandInformationServicesEstimatednumberofcancercasesdiagnosedinwomeninJapanin2022,bycancersite(in1,000s)ProjectednumberoffemalecancercasesJapan2022,bycancersiteNumberofincidencesinthousands0102030405060708090100Breast94.3Colon/rectum68.7LungStomach42.541Uterus28.6Pancreas21.9Malignantlymphoma17.2ThyroidOvaryLiver13.813.112.912.5SkinGallbladderandbileductsKidneyandotherurinaryorgans119.914Description:In2022,thenumberofbreastcancercasesamongwomeninJapanreachedapproximately94.3thousand,whichmadeitthemostcommontypeofcancerforwomen.TheestimatedtotalnumberofcancercasesforJapanesewomeninthatyearamountedtoalmost435thousand.ReadmoreNote(s):Japan;2022Source(s):CenterforCancerControlandInformationServicesCHAPTER

03MortalityriskCancermortalityriskinJapanin2021,bygenderCancermortalityriskJapan2021,bygender30%26.2%25%20%15%10%5%17.7%0%MenWomen16Description:In2021,thelifetimecancermortalityriskformeninJapanstoodat26.2percent.Inotherwords,oneinfourJapanesemenisestimatedtodieofcancer.Theriskforwomenwaslower.

ReadmoreNote(s):Japan;2021Source(s):CenterforCancerControlandInformationServices;FoundationforPromotionofCancerResearchCancermortalityriskofmeninJapanin2021,byageCancermortalityriskofmenJapan2021,byage30%25%20%15%10%26.2%13.4%5.3%5%1.6%0.4%0.2%0%upto39yearsupto49yearsupto59yearsupto69yearsupto79yearsLifetime17Description:In2021,thecancermortalityriskformeninJapanaged39yearsandyoungerstoodataround0.2,whilethelifetimeriskreachedover26percent.Inotherwords,oneinfourJapanesemenwasestimatedtodieofcancer.

ReadmoreNote(s):Japan;2021Source(s):CenterforCancerControlandInformationServices;FoundationforPromotionofCancerResearchCancermortalityriskofwomeninJapanin2021,byageCancermortalityriskofwomenJapan2021,byage20%18%16%14%12%10%8%17.7%8%6%3.9%4%2%0%1.7%0.6%0.2%upto39yearsupto49yearsupto59yearsupto69yearsupto79yearsLifetime18Description:In2021,thecancermortalityriskforwomeninJapanaged39yearsandyoungerstoodataround0.2,whilethelifetimeriskreachedalmost18percent.Inotherwords,oneinsixJapanesewomenwasestimatedtodieofcancer.

ReadmoreNote(s):Japan;2021Source(s):CenterforCancerControlandInformationServicesCumulativelifetimeriskofcancermortalityformeninJapanin2021,bycancersiteCumulativelifetimeriskofcancermortalityformenJapan2021,bycancersiteLifetimeriskofcancermortality2%

3%0%1%4%5%6%7%Lung,tracheaColon/RectumStomach6.2%3.3%3.2%Pancreas2.2%2.1%1.9%ColonLiverProstate1.6%GallbladderandbileductsRectum1.2%1.1%1%0.9%0.7%EsophagusMalignantlymphomaLeukemiaThyroid0.1%19Description:In2021,thelifetimeriskofcancermortalityformeninJapanwashighestforlungandtracheacancerwitharound6.2percent.Inotherwords,aboutonein16Japanesemaleswasestimatedtodiefromlungortracheacancer.

ReadmoreNote(s):Japan;2021Source(s):CenterforCancerControlandInformationServicesCumulativelifetimeriskofcancermortalityforwomeninJapanin2021,bycancersiteCumulativelifetimeriskofcancermortalityforwomenJapan2021,bycancersiteLifetimeriskofcancermortality1.0%

1.5%0.0%Colon/Rectum0.5%2.0%2.5%3.0%2.7%Lung,trachea2.5%Pancreas2.1%2.1%ColonBreast1.7%Stomach1.6%Gallbladderandbileducts0.9%0.9%LiverUterus0.8%LeukemiaOvary0.7%0.6%0.6%RectumCervixuteri0.3%20Description:In2021,thelifetimeriskofcancermortalityforwomeninJapanwasthehighestforcolonandrectumcancerwithapproximately2.7percent.Inotherwords,aboutonein49Japanesewomenwasestimatedtodieofcolonorrectumcancer.

ReadmoreNote(s):Japan;2021Source(s):CenterforCancerControlandInformationServicesCHAPTER

04CancerinchildrenNumberofcancercasesamongchildreninJapanfrom2012to2021Numberofchildren'scancercasesinJapan2012-20211,4001,1741,2001,00080060040020001,1411,111983939802582554509446201220132014201520162017201820192020202122Description:In2021,thenumberofcancercasesamongchildreninJapanaccountedfor1,174,reachingadecadehigh.Overall,thenumberofchildren'scancercasesinJapanhasbeenonanupwardtrajectorysince2012.

ReadmoreNote(s):Japan;2012to2021Source(s):MHLW(Japan)NumberofcancercasesamongchildreninJapanin2021,bytypeofcancerNumberofchildren'scancercasesinJapan2021,bytypeofcancerNumberofcancercases050100150200250300350400BraintumorLymphoma376193Others173NeuroblastomaGermcelltumorLivertumor1348372KidneytumorRhabdomyosarcomaEwingsarcoma63532723Description:In2021,thenumberofbraintumorcasesamongchildreninJapanstoodat376,accountingforthehighestnumberamongdifferentcancertypesinchildren.Incontrast,thenumberofEwingsarcomacasesamountedto27.

ReadmoreNote(s):Japan;2021Source(s):MHLW(Japan)NumberofcancercasesinchildrenandyoungadultsinJapanin2020,byagegroup(in1,000s)NumberofcancercasesinchildrenandyoungadultsJapan2020,byage25,00020,00015,00010,00020,8105,0002,09400to14years15to39years24Description:In2020,therewere2,094cancercasesamongchildrenunder14inJapan.Thenumberofcancercasesamong15to39yearoldsinJapanamountedto20,810thatyear.

ReadmoreNote(s):Japan;2020Source(s):FDMA(Japan);MHLW(Japan)CHAPTER

05CancerscreeningsNumberofpeopleundergoinghealthcheck-upsinJapanfromfiscalyear2017to2021(in1,000s)Numberofpeopleundergoinghealthcheck-upsJapanFY2017-2021140125.19122.58121.83119.62120100806040200114.422017201820192020202126Description:Infiscalyear2021,approximately120thousandpeopleunderwenthealthcheck-upsinJapan.Thefigureincreasedcomparedtoaround114thousandpeopleinthepreviousyear.

ReadmoreNote(s):Japan;fiscalyear2017to2021;theJapanesefiscalyearstartsonApril1ofthestatedyearandendsonMarch31ofthefollowingyearSource(s):MHLW(Japan)NumberofpeoplereceivingcancerscreeningsatmunicipalitiesinJapaninfiscalyear2022,bytypeofcancer(inmillions)NumberofpeoplereceivingcancerscreeningsatmunicipalitiesJapanFY2022,bytypeNumberofpeopleinmillions0.00.51.01.52.02.53.03.54.0ColoncancerCervicalcancerLungcancer3.463.363BreastcancerStomachcancer2.131.4227Description:Around3.46millioncoloncancerscreeningswereconductedatmunicipalitiesinJapaninthefiscalyear2022.MunicipalitiesinJapanprovidestomachcancerscreeningsforpeopleagedbetween50and69yearsold,lungcancer,coloncancer,andbreastcancerscreeningsforpeopleagedbetween40and69yearsold,andcervicalcancerscreeningsforpeopleagedfrom20to69yearsold.

ReadmoreNote(s):Japan;fiscalyear2022;theJapanesefiscalyearstartsonApril1ofthestatedyearandendsonMarch31ofthefollowingyearSource(s):MHLW(Japan)NumberofdiscoveriesofcanceraftercancerscreeningsinJapaninfiscalyear2020,bysiteNumberofdiscoveriesaftercancerscreeningsJapanFY2020,bysiteNumberofdiscoveries3,00001,0002,0004,0005,0006,0007,000BreastcancerColorectalcancerStomachcancerCervicalcancerLungcancer5,9935,2101,41783673828Description:Infiscalyear2020,thehighestnumberofdiscoveriesaftercancerscreeninginJapanoccurredinbreastcanceramongthefivecancersites,with5,993cases.Colorectalcancerfollowedwith5,210cases.

ReadmoreNote(s):Japan;fiscalyear2020;theJapanesefiscalyearstartsonApril1ofthestatedyearandendsonMarch31ofthefollowingyearSource(s):MHLW(Japan)ShareofpeoplewhodidacancerscreeninginthepasttwoyearsinJapanasofAugust2023ShareofpeoplewhodidacancerscreeninginthepasttwoyearsJapan202340%34.9%35%30%25%20%15%10%5%32.8%20.8%9.9%1.7%0%Ididacancerscreeningwithin

Ididacancerscreeningwithinthepastoneyear

thepasttwoyearsNoresponseIdidacancerscreeningmore

Ihaveneverdoneacancerthantwoyearsago

screening29/statistics/1430208/japan-share-of-people-who-did-a-cancer-screening-in-the-past-two-yearsAccordingtoagovernmentsurveyconductedinJapanin2023,morethan42percentofrespondentsreportedtheydidacancerscreeninginthepasttwoyears.Incontrast,34.9percentofrespondentsansweredtheyhadneverdoneacancerscreening.ReadmoreNote(s):Japan;July6toAugust13,2023;1,626respondents;18yearsandolderSource(s):CabinetOfficeJapan;MHLW(Japan)MainreasonstodoacancerscreeninginJapanasofAugust2023MainreasonstodoacancerscreeningJapan2023Shareofrespondents0%5%10%15%20%25%30%35%Someoneclose,suchasfamilyorfriends,hadcancerRecommendedduringahealthcheckatworkorschoolLearnedaboutitthroughlocalgovernmentannouncementsReccomendedbyahealthcareprofessionalduringtreatmentforanotherillnessRecommendedbyfamily28.8%28.1%23.5%16.9%12.2%LearnedaboutitthroughTVorradio4%RecommendedbyasupervisororcolleagueatworkReceivedcancereducationatworkorschool2.9%1.9%1.3%LearnedaboutitthroughnewspapersDiscoveredthroughinternetnewsoronlineadvertising,excludingsocialmediaLearnedaboutitthroughsocialmediasuchasTwitter,LINE,Facebook,InstagramOther0.9%0.4%18.4%Noresponse0.7%30Description:AccordingtoagovernmentsurveyconductedinJapanin2023,28.8percentofrespondentsstatedtheydidacancerscreeningbecausesomeoneclose,suchasfamilyorfriends,hadcancer.28.1percentofrespondentsansweredtheydidacancerscreeningbecausetheywererecommendedtodosoduringahealthcheckatworkorschool.ReadmoreNote(s):Japan;July6toAugust13,2023;694respondents;18yearsandolder;onlypeoplewhodidcancerscreeninginthelasttwoyearswereaskedSource(s):CabinetOfficeJapan;MHLW(Japan)MainreasonstonotdoacancerscreeninginJapanasofAugust2023MainreasonstonotdoacancerscreeningJapan2023Shareofrespondents0%5%10%15%20%25%30%ItispossibletovisitamedicalfacilityatanytimewhenfeelingconcernedCostinafinancialburden23.9%23.2%21.2%NotimetoundergoscreeningConfidentinhealthanddonotfeeltheneedUncertaintyaboutthetestandfearofdiscomfortAfraidoffindingouttheyhavecancerLackofawarenessaboutcancerscreeningConcernsaboutpotentialoversightevenafterascreeningInconvenientlocationforscreening16.6%16.6%16.2%8.1%6.4%6.2%Otherreasons10.9%11.2%NotwithinthetargetaudienceforcancerscreeningNoresponse1.7%31Description:AccordingtoagovernmentsurveyconductedinJapanin2023,23.9percentofrespondentsstatedtheydonotdoacancerscreeningbecausetheycanvisitamedicalfacilityatanytimewhentheyfeelconcerned.23.2percentofrespondentsansweredtheydonotdoacancerscreeningbecauseitcostsandbecomesafinancialburden.ReadmoreNote(s):Japan;July6toAugust13,2023;905respondents;18yearsandolder;onlypeoplewhoansweredthattheydidnotdoacancerscreeninginthelasttwoyearswereaskedSource(s):CabinetOfficeJapan;MHLW(Japan)CHAPTER

06OncologyNumberofgeneralhospitalswithbreastoncologydepartmentsinJapanfrom2014to2022NumberofgeneralhospitalswithbreastoncologydepartmentsJapan2014-20221,2001,0001,0831,0491,039986958915832788800600400200073920142015201620172018201920202021202233Description:AsofOctober2022,atotalofaround1,080breastsurgerydepartmentswereavailableingeneralhospitalsinJapan.Thatyear,breastoncologydepartmentsaccountedforapproximately15.3percentofalldepartmentsthatexistedingeneralhospitalsinJapan.ReadmoreNote(s):Japan;2014to2022;asofOctober1Source(s):MHLW(Japan)NumberofnewlycertifiedgeneralclinicaloncologistsinJapanfromfiscalyear2019to2022NumberofnewlycertifiedgeneralclinicaloncologistsJapanFY2019-20221,0009309008007006005004003002001000798711646201920202021202234Description:Infiscalyear2022,thenumberofnewlycertifiedgeneralclinicaloncologistswas646.Thefiguredecreasedcomparedto798inthepreviousyear.

ReadmoreNote(s):Asia,Japan;fiscalyear2019to2022;theJapanesefiscalyearstartsonApril1ofthestatedyearandendsonMarch31ofthefollowingyearSource(s):JapaneseBoardofCancerTherapyNumberofoncologistsinJapaninfiscalyear2023,bygender(in1,000s)NumberofoncologistsJapanFY2023,bygenderNumberofoncologistsinthousands024681012141618Male15.32Female2.6935Description:Infiscalyear2023,thenumberofmalegeneralclinicaloncologistsinJapanwasover15.3thousand.Incontrast,thenumberoffemalegeneralclinicaloncologistswasonlyaround2.7thousand.

ReadmoreNote(s):Asia,Japan;fiscalyear2023;theJapanesefiscalyearstartsonApril1ofthestatedyearandendsonMarch31ofthefollowingyearSource(s):JapaneseBoardofCancerTherapyNumberofoncologistsinJapanin2023.bytypeNumberofoncologistsJapan2023,bytypeNumberofoncologists02,0004,0006,0008,00010,00012,00014,00016,00018,00020,000Generalclinicaloncologists18,009Dentalandoraloncologists63536Description:In2023,outof18,644oncologistsinJapan,18,009weregeneralclinicaloncologists.Additionally,therewere635dentalandoraloncologists.ReadmoreNote(s):Asia,Japan;2023Source(s):JapaneseBoardofCancerTherapyNumberofoncologistsinJapaninfiscalyear2023,bydepartmentNumberofoncologistsJapanFY2023,bydepartmentNumberofoncologists01,0002,0003,0004,0005,0006,0007,0008,000SurgicalSocietySocietyofInternalMedicine7,5244,367SocietyofObstetricsandGynecologyUrologicalAssociation1,9181,695RadiologicalSocietySocietyofOtorhinolaryngology-HeadandNeckSurgeryNeurosurgicalSociety636578480PediatricSocietyOrthopaedicAssociation257257DermatologicalAssociationSocietyofPlasticandReconstructiveSurgerySocietyofAnesthesiologists159793210SocietyofLaboratoryMedicine37/statistics/1448202/japan-number-of-oncologists-by-departmentInfiscalyear2023,thehighestnumberofoncologistsinJapanbydepartmentwasintheSurgicalSociety,witharound7.5thousandoncologists.Thesecond-highestnumberwasintheInternalMedicineSociety,withalmost4.4thousandoncologists.ReadmoreNote(s):Asia,Japan;fiscalyear2023;theJapanesefiscalyearstartsonApril1ofthestatedyearandendsonMarch31ofthefollowingyearSource(s):JapaneseBoardofCancerTherapyNumberofgeneralclinicaloncologistsinJapanin2023,byprefectureNumberofgeneralclinicaloncologistsJapan2023,byprefectureNumberofoncologists05001,0001,5002,0002,5003,000TokyoOsaka2,6221,629KanagawaAichiFukuokaHyogo1,181829818811HokkaidoSaitamaChiba763719694Kyoto555ShizuokaHiroshimaOkayama45937035338Description:In2023,thenumberofgeneralclinicaloncologistsinJapanwashighestinTokyo,withover2.6thousand,makingTokyotheprefecturewiththehighestnumberofoncologists.Theprefecturewiththesecond-highestnumberwasOsaka,with1.6thousandoncologists.ReadmoreNote(s):Asia,Japan;2023Source(s):JapaneseBoardofCancerTherapyCHAPTER

07ImpactonJapanesepeopleImpressiononcancerinJapanasofAugust2023ImpressiononcancerJapan202360%49.3%50%40%30%20%10%0%41%5.2%2.6%2%IamafraidofcancerIamratherafraidofcancerNoresponseIamrathernotafraidofcancerIamnotafraidofcancer40Description:AccordingtoagovernmentsurveyconductedinJapanin2023,49.3percentofrespondentsreportedthattheywereafraidofcancer.Incontrast,twopercentofrespondentsansweredtheywerenotafraidofcancer.

ReadmoreNote(s):Japan;July6toAugust13,2023;1,626respondents;18yearsandolderSource(s):CabinetOfficeJapan;MHLW(Japan)MostcommonreasonstobeafraidofcancerinJapanasofAugust2023MostcommonreasonstobeafraidofcancerJapan2023Shareofrespondents0%10%20%30%40%50%60%70%80%90%ThereisapossibilityofdyingfromcancerCanceritselforitstreatmentcancausesymptomssuchaspainCancertreatmentandrecoverymayplaceaburdenonfamilyorclosefriendsCostofcancertreatmentcanbehigh81.6%62.6%58.6%57.7%Cancermayleadtoaprolongedabsencefromworkorschool,orevenquittingThereisurcertaintyanddistressinchoosingtherighttreatmentItcanbechallengingtofindanappropriatemedicalfacilityforcancertreatmentEvenifcanceriscured,theremaybelingeringaftereffectsOther32.2%29.6%27.6%26%2.8%0.7%Noresponse41Description:AccordingtoagovernmentsurveyconductedinJapanin2023,81.6percentofrespondentsansweredthattheyareafraidofcancerbecausethereisapossibilityofdyingfromcancer.62.6percentofrespondentsreportedtheyareafraidofcancerbecausecanceritselforitstreatmentcancausesymptomssuchaspain.ReadmoreNote(s):Japan;July6toAugust13,2023;18yearsandolder;onlypeoplewhoansweredtheyareafraidof,orsomewhatafraidofcancer,wereaskedSource(s):CabinetOfficeJapan;MHLW(Japan)OpiniononcancerimmunotherapyinJapanasofAugust2023OpiniononcancerimmunotherapyJapan2023Shareofrespondents0%10%20%30%40%50%60%Iwouldreceivecancerimmunotherapyifmydoctorrecomme